RSV vaccines would dramatically reduce disease burden if wid

Respiratory syncytial virus (RSV) vaccines recently approved for people 60 and older would dramatically reduce the disease's significant burden of illness and death in the United States if they were widely adopted like annual influenza vaccines, a new study has found.

Related Keywords

United States , American , Alison Galvani , Seyed Moghadas , York University , Yale University , Drug Administration , Yale Center , Prevention Advisory Committee On Immunization Practices , Yale School Of Public Health , Centers For Disease , Disease Control , Advisory Committee , Some Medicare , Stender Families Professor , Microbial Diseases , Yale School , Infectious Disease Modeling , Clinical Infectious , Flu , Efficacy , Epidemiology , Health Care , Immunization , Infectious Diseases , Influenza , Medicare , Ortality , Espiratory , Respiratory Syncytial Virus , Vaccine , Virus ,